CPHPC

Ligand id: 8256

Name: CPHPC

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 115.22
Molecular weight 340.16
XLogP -0.15
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ et al.. (2010)
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.
Nature468 (7320): 93-7. [PMID:20962779]
2. Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN et al.. (2010)
Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
Br. J. Haematol.148 (5): 760-7. [PMID:20064157]
3. Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL et al.. (2009)
Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.
Proc. Natl. Acad. Sci. U.S.A.106 (18): 7619-23. [PMID:19372378]
4. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C et al.. (2002)
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
Nature417 (6886): 254-9. [PMID:12015594]
5. Wermuth CG. (2004)
Selective optimization of side activities: another way for drug discovery.
J. Med. Chem.47 (6): 1303-14. [PMID:14998318]